The Crohn’s disease (CD) therapy market is expected to see increasing use of biologics / targeted oral therapies and grow steadily over the next decade. The well-established TNF-α inhibitors (e.g., infliximab, adalimumab [AbbVie / Eisai’s Humira, biosimilars]), together with non-TNF biologics (i.e., Takeda’s Entyvio and Janssen’s Stelara), have transformed the treatment landscape for CD, especially for moderate to severe disease, despite these drugs’ efficacy limitations and safety risks. The impending entry of several new therapies offering more-convenient formulations and/or novel mechanisms of action (e.g., Galapagos / Gilead’s filgotinib, AbbVie’s risankizumab and upadacitinib, Janssen’s guselkumab) will further improve treatment and intensify market competition. Together with these trends, the continuing generic erosion of conventional agents and the availability of biosimilar TNF-α inhibitors will constrain CD therapy sales.

Questions Answered

  • What are KOLs’ opinions of current targeted therapies (e.g., infliximab, adalimumab, Stelara, Entyvio)? How have biosimilars influenced treatment practices? What factors drive treatment decisions?
  • What do KOLs think about emerging therapies (e.g., filgotinib, risankizumab, upadacitinib, guselkumab)? What impact will the stem-cell therapy Alofisel (TiGenix / Takeda) and oral therapies have on the CD treatment algorithm?
  • Which emerging agents are likely to be most successful in targeting TNF-refractory patients and gaining uptake in the CD market?
  • How will the market evolve over the next ten years?

Content Highlights

Geographies: United States, EU5, Japan.

Primary research: 24 country-specific interviews with thought-leading gastroenterologists supported by survey data collected for this and other DRG research.

Epidemiology: Diagnosed prevalence of Crohn’s disease by country, segmented by disease activity.

Forecast: Ten-year, annualized, drug-level sales and patient share of key Crohn’s disease therapies through 2029, segmented by brands/generics.

Emerging therapies: ​​​​​​Phase III/PR: ~9 drugs; coverage of select preclinical, Phase I and Phase II products.

Product Description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Table of contents

  • Crohn's Disease - Landscape & Forecast - Disease Landscape & Forecast
    • COVID-19
      • Key Findings
        • Key Updates
          • Q1 2021
            • March 2021
            • February 2021
            • January 2021
          • Q4 2020
          • Market Outlook
            • COVID-19: Areas of Potential Forecast Impact
              • Expert Insight: COVID-19
            • Key Findings
              • Market Share of Drug Classes for Crohn's Disease: 2019
              • Market Share of Drug Classes for Crohn's Disease: 2029
              • Patient Share of Major Drug Classes for Crohn's Disease in the Maintenance Setting: 2019-2029
              • Patient Share of Major Drug Classes for Crohn's Disease in the Acute Setting: 2019-2029
              • Crohn's Disease SWOT Analysis
            • Market Drivers and Constraints
              • What Factors Are Driving the Market for Crohn's Disease?
              • What Factors Are Constraining the Market for Crohn's Disease?
            • Drug-Class-Specific Trends
              • Total Sales and Patient Share of TNF-Alpha Inhibitors: 2019-2029
              • Total Sales and Patient Share of IL-12/23 Inhibitors: 2019-2029
              • Total Sales and Patient Share of CAM Inhibitors: 2019-2029
              • Total Sales and Patient Share of IL-23 Inhibitors: 2019-2029
              • Total Sales and Patient Share of JAK Inhibitors: 2019-2029
              • Sales of Darvadstrocel (Alofisel) by Country: 2019-2029
              • Total Sales and Patient Share of Ozanimod: 2019-2029
          • Forecast
            • Market Forecast Assumptions
            • Market Forecast Dashboard
          • Etiology and Pathophysiology
            • Disease Overview
              • Key Pathways and Drug Targets
                • Key Pathways in Crohn's Disease
                • Key Drug Targets and Their Biological Function
            • Epidemiology
              • Key Findings
                • Epidemiology Populations
                  • Methods
                  • Sources Used for Diagnosed Prevalent Cases of Crohn's Disease
                  • Diagnosed Prevalent Cases of Crohn's Disease: 2019-2029 (thousands)
                  • Methods
                  • Sources Used for Diagnosed Prevalent Cases of Crohn's Disease by Disease Activity
                  • Diagnosed Prevalent Cases of Crohn's Disease by Disease Activity: 2019-2029 (thousands)
                  • Drug-Treated Prevalent Cases of Crohn's Disease: 2019-2029
              • Current Treatment
                • Key Findings
                  • Treatment Goals
                    • Key Endpoints Used in Clinical Trials for Crohn's Disease
                  • Key Current Therapies
                    • Overview
                    • Mechanism of Action of Key Current Drug Classes Used for Crohn's Disease
                    • Current Treatments Used for Crohn's Disease
                    • Market Events Impacting the Use of Key Current Therapies in Crohn's Disease
                    • Expert Insight: TNF-Alpha Inhibitors
                    • Advantages and Disadvantages of Infliximab
                    • Advantages and Disadvantages of Adalimumab
                    • Advantages and Disadvantages of Cimzia
                    • Advantages and Disadvantages of Tysabri
                    • Advantages and Disadvantages of Entyvio
                    • Expert Insight: Entyvio
                    • Key Ongoing Clinical Trials of Entyvio in the Treatment of Crohn's Disease
                    • Advantages and Disadvantages of Stelara
                    • Expert Insight: Stelara
                    • Key Ongoing Clinical Trials of Stelara in the Treatment of Crohn's Disease
                    • Advantages and Disadvantages of 5-ASAs
                    • Expert Insight: 5-ASAs
                    • Advantages and Disadvantages of Immunosuppressants
                    • Expert Insight: Immunosuppressants
                    • Advantages and Disadvantages of Corticosteroids
                    • Expert Insight: Corticosteroids
                    • Advantages and Disadvantages of Antibiotics
                  • Medical Practice
                    • Overview
                    • Country-Specific Crohn's Disease Treatment Guidelines
                    • Factors Influencing Drug Selection in Crohn's Disease
                    • Treatment Decision Tree for Crohn's Disease: United States
                    • Treatment Decision Tree for Crohn's Disease: Europe
                    • Treatment Decision Tree for Crohn's Disease: Japan
                • Unmet Need Overview
                  • Current and Future Attainment of Unmet Needs in Crohn's Disease
                  • Top Unmet Needs in Crohn's Disease: Current and Future Attainment
                • Emerging Therapies
                  • Key Findings
                    • Pipeline Trends in Crohn's Disease
                  • Key Emerging Therapies
                    • Key Therapies in Development for Crohn's Disease
                    • Estimated Launch Dates of Key Emerging Therapies for the Treatment of Crohn's Disease
                    • Risankizumab (Skyrizi) Profile
                    • Mirikizumab Profile
                    • Guselkumab (Tremfya) Profile
                    • Brazikumab Profile
                    • Expert Insight: IL-23 Inhibitors
                    • Darvadstrocel (Alofisel) Profile
                    • Expert Insight: Darvadstrocel (Alofisel)
                    • Prochymal Profile
                    • Etrolizumab Profile
                    • Expert Insight: Etrolizumab
                    • Filgotinib (Jyseleca) Profile
                    • Expert Insight: Filgotinib (Jyseleca)
                    • Upadacitinib (Rinvoq) Profile
                    • Expert Insight: Upadacitinib (Rinvoq)
                    • Ozanimod (Zeposia) Profile
                    • Expert Insight: Ozanimod (Zeposia)
                    • Etrasimod Profile
                    • RHB-104 Profile
                  • Early-Phase Pipeline Analysis
                    • Select Compounds in Phase II Development for Crohn's Disease
                  • Key Discontinuations and Failures in Crohn's Disease
                  • Access and Reimbursement Overview
                    • Region-Specific Reimbursement Practices
                      • Key Market Access Considerations in Crohn's Disease: United States
                      • General Reimbursement Environment: United States
                      • Key Market Access Considerations in Crohn's Disease: EU5
                      • General Reimbursement Environment: EU5
                      • Key Market Access Considerations in Crohn's Disease: Japan
                      • General Reimbursement Environment: Japan
                  • Appendix
                    • Key Abbreviations Related to Crohn's Disease
                    • Brands, Marketers, and Generic Availability of Current Therapies Used for Crohn's Disease, by Market
                    • Crohn's Disease Bibliography

                Author(s): Ritesh Gupta, Ph.D.; Abey John, M.P.H.

                Ritesh Gupta, Ph.D., is a principal analyst on the Immune and Inflammatory Disorders team at DRG, part of Clarivate. He has many years of experience in competitive intelligence, scientific analysis, and market opportunity assessment and has worked in various therapeutic areas to provide strategic recommendations to pharma companies. He holds a Ph.D. in cell biology from the Max Delbrück Center for Molecular Medicine in Berlin, where he worked on developing novel inhibitors for HGF/MET-signaling pathways.

                Abey John, M.P.H., is an epidemiologist at DRG, part of Clarivate. Prior to joining DRG, he worked with Jhpiego (an affiliate of Johns Hopkins Medical University) in implementing family planning health programs in India in collaboration with the government of India. He also has worked at the grassroots level as a health team manager to help the rural population living in the foothills of the Himalayas. He holds a master’s degree in public health.

                 


                Related Reports

                Crohn's Disease | Treatment Algorithms: Claims Data Analysis | Pediatric | US | 2020

                Children with Crohn’s disease (CD) have a more-complicated disease course compared with adult patients. However, similar to adult CD, the primary goal of the treatment of pediatric CD is to induce...

                View Details